Fol. Biol. 2011, 57, 1-2
https://doi.org/10.14712/fb2011057010001
Interleukin 12 in Cancer Treatment
References
1. , K., Barnes, M. N., Fewell, J., Lewis, D. H., Alvarez, R. D. (2010) Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of recurrent ovarian cancer. Gene Ther. 17, 360-369.
<https://doi.org/10.1038/gt.2009.159>
2. , P., Prieto, J., Gonzalez-Aseguinolaza, G. (2009) Advances in interleukin-12 gene therapy for acquired liver diseases. Curr. Gene Ther. 9, 62-71.
<https://doi.org/10.2174/156652309787909553>
3. , J. (1996) Gene transfer for immunotherapy of cancer (Editorial). Gene Ther. 3, 944-945.
4. , J., Den Otter, W., Huland, E. (2000) Local cytokine therapy of cancer: interleukin-2, interferons and related cytokines. Cancer Immunol. Immunother. 49, 116-122.
5. , J. (2008) Genetically modified cellular vaccines for therapy of human papillomavirus type 16 ( HPV16 )-associated tumours. Curr. Cancer Drug Targets 8, 180-186.
<https://doi.org/10.2174/156800908784293596>
6. , J., Šímová, J. (2009) Genetically modified cellular vaccines against human papilloma virus type 16 (HPV16)-associated tumours: adjuvant treatment of minimal residual tumour disease after surgery/chemotherapy. J. BUON 14 (Suppl.), S169-S174.
7. , A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., Heller, R. (2008) Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J. Clin. Oncol. 26, 5896-5903.
<https://doi.org/10.1200/JCO.2007.15.6794>
8. , G. (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4, 11-22.
<https://doi.org/10.1038/nrc1252>
9. , M. A., Neurath, M. F. (2010) Anticancer properties of the IL-12 family – focus on colorectal cancer. Curr. Med. Chem. 17, 3303-3308.
<https://doi.org/10.2174/092986710793176366>
10. , E. G. (2003) Dendritic cell-based cancer immunotherapy. Semin. Oncol. 30, 23-29.
<https://doi.org/10.1016/S0093-7754(03)00229-X>
11. , P., Kärre, K. (2000) Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur. J. Immunol. 30, 1088-1093.
<https://doi.org/10.1002/(SICI)1521-4141(200004)30:4<1088::AID-IMMU1088>3.0.CO;2-O>
12. , S., Lotfipour, F., Dass, C. (2010) Nanoparticlemediated interleukin-12 cancer gene therapy. J. Pharm. Pharm. Sci. 13, 472-485.
13. , L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J., Elzaouk, L., Pavlovic, J., Moelling, K. (2005) Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. 16, 35-48.
<https://doi.org/10.1089/hum.2005.16.35>
14. , M., Bieblová, J., Jandlová, T., Vonka, V., PajtaszPiasecka, E., Reinis, M. (2006) Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int. J. Oncol. 28, 253-259.
15. , M., Bieblová, J., Bubeník, J., Reinis, M. (2008) IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets. Int. J. Oncol. 32, 499-507.
16. , M., Bieblová, J., Rossowska, J., Kuropka, P., PajtaszPiasecka, E., Bubeník, J., Reinis, M. (2009) HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy. Int. J. Oncol. 34, 173-179.
17. , M., Tahara, H. (2009) Cytokine gene-mediated immunotherapy: current status and future perspectives. Cancer Sci. 100, 1389-1396.
<https://doi.org/10.1111/j.1349-7006.2009.01202.x>
18. , W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S. S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J. A., Nam, S. J., Yang, J. H., Son, Y. I., Baek, C. H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D. W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J. H., Park, M. H., Kong, G. S., Park, E. Y., Kang, Y. K., Bang, Y. J., Paik, N. S., Lee, S. N., Kim, S. H., Kim, S., Robbins, P. D., Tahara, H., Lotze, M. T., Park, C. H. (2001) Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum. Gene Ther. 12, 671-684.
<https://doi.org/10.1089/104303401300057388>
19. Klein, J., Hořejší, V. (1997) Immunology, p.721 (Blackwell Science, Oxford).
20. , M. Q., Jacobus, S., Blood, E. A., Kay, N. E., Rajkumar, S. V., Greipp, P. R. (2009) Phase II study of interleukin-12 for treatment of plateau phase multiple myeloma (E1A96): a trial of the Eastern Cooperative Oncology Group. Leuk. Res. 33, 1485-1489.
<https://doi.org/10.1016/j.leukres.2009.01.020>
21. , M., Rizzo, M., Alaniz, L., Piñero, F., García, M., Atorrasagasti, C., Aquino, J. B., Rozados, V., Scharovsky, O. G., Matar, P., Mazzolini, G. (2009) A novel synergistic combination of cyclophosphamide and gene transfer of interleukin-12 eradicates colorectal carcinoma in mice. Clin. Cancer Res. 15, 7256-7265.
<https://doi.org/10.1158/1078-0432.CCR-09-1861>
22. , C., Angiolillo, A. L., Tosato, G. (1996) Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 87, 3877-3882.
<https://doi.org/10.1182/blood.V87.9.3877.bloodjournal8793877>
23. , Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., Schadendorf, D. (1998) Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther. 5, 481-490.
<https://doi.org/10.1038/sj.gt.3300619>
24. , P. L., Strong, T. V., Bucy, R. P ., Allen, K. O., Carlisle, R. R., Moore, S. E., Lobuglio, A. F., Conry, R. M. (2005) Intratumoral administration of a recombinant canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum. Gene Ther. 16, 91-100.
<https://doi.org/10.1089/hum.2005.16.91>
25. , K., Meko, J. B., Tsung, Y. L., Peplinski, G. R., Norton, J. A. (1998) Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J. Immunol. 160, 1369-1377.
<https://doi.org/10.4049/jimmunol.160.3.1369>
